Our Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is provided in addition to the accompanying condensed consolidated financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash flows. This MD&A is organized as follows:

• Business Overview and Outlook. High level discussion of our operating results and significant known trends that affect our business.

• Results of Operations. Detailed discussion of our revenues and expenses.

• Liquidity and Capital Resources. Discussion of key aspects of our statements of cash flows, changes in our financial position, and our financial commitments.

• Off-Balance Sheet Arrangements. We have no significant off-balance sheet arrangements.

• Critical Accounting Policies and Estimates. Discussion of significant changes since our most recent Annual Report on Form 10-K that we believe are important to understanding the assumptions and judgments underlying our financial statements.

This MD&A discussion contains forward-looking statements that involve risks and uncertainties. Please see "Consideration Regarding Forward-Looking Statements" at the end of this MD&A section for additional factors relating to such statements. This MD&A should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this report and our Annual Report on Form 10-K for the fiscal year ended January 1, 2012. Operating results are not necessarily indicative of results that may occur in future periods.

Business Overview and Outlook

This overview and outlook provides a high level discussion of our operating results and significant known trends that affect our business. We believe that an understanding of these trends is important to understanding our financial results for the periods being reported herein as well as our future financial performance. This summary is not intended to be exhaustive, nor is it intended to be a substitute for the detailed discussion and analysis provided elsewhere in this Quarterly Report on Form 10-Q.

About Illumina

We are a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. Using our proprietary technologies, we provide a comprehensive line of genetic analysis solutions, with products and services that address a broad range of highly interconnected markets, including sequencing, genotyping, gene expression, and molecular diagnostics. Our customers include leading genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies.

Our broad portfolio of instruments, consumables, and analysis tools are designed to simplify and accelerate genetic analysis. This portfolio addresses the full range of genomic complexity, price points, and throughputs, enabling researchers to select the best solution for their scientific challenge. In 2007, through our acquisition of Solexa, Inc., we acquired our proprietary sequencing by synthesis (SBS) technology that is at the heart of our leading-edge sequencing instruments. These systems can be used to efficiently perform a range of nucleic acid (DNA, RNA) analyses on large numbers of samples. For more focused studies, our array-based solutions provide ideal tools to perform genome-wide association studies (GWAS) involving single-nucleotide polymorphism (SNP) genotyping and copy number variation (CNV) analyses, as well as gene expression profiling and other DNA, RNA, and protein studies. In 2010, through our acquisition of Helixis, Inc., we expanded our instrument portfolio to include real-time polymerase chain reaction (PCR), one of the most widely used technologies in life sciences. To further enhance our genetic analysis workflows, in 2011 we acquired Epicentre Technologies Corporation, a leading provider of nucleic acid sample preparation reagents and specialty enzymes for sequencing and microarray applications.

Our financial results have been, and will continue to be, impacted by several significant trends, which are described below. While these trends are important to understanding and evaluating our financial results, this discussion should be read in conjunction with our condensed consolidated financial statements and the notes thereto in Item 1, Part I of this report, and the other transactions, events, and trends discussed in "Risk Factors" in Item 1A, Part II of this report and Item 1A of our Annual Report on Form 10-K for the fiscal year ended January 1, 2012.

Funding Environment

We believe the uncertainty surrounding the levels of government and academic research funding in the United States and Europe will continue in the second half of 2012 and into 2013, which could lead to purchasing delays and could negatively impact our business. There remains significant uncertainty concerning government and academic research funding worldwide as governments in the United States and Europe, in particular, focus on reducing fiscal deficits while at the same time confronting slow economic growth.

While many of our customers receive funding from government agencies to purchase our products we are seeing less of a dependence on government funding, exemplified by MiSeq orders that are weighted more heavily to non-academic customers. However, we estimate that approximately one-third of our total revenue is derived, directly or indirectly, from funding provided by the U.S. National Institute of Health (NIH). Based on the fiscal year 2012 Congressional budget, the adjusted fiscal 2012 NIH budget increased 1% as compared to fiscal 2011 levels. The significance and timing of any reductions to the NIH budget beyond fiscal 2012 may be significantly impacted by the sequestration provisions of the Budget Control Act of 2011 and by whether these provisions remain in effect. In addition, the U.S. Department of Health and Human Services (HHS), of which the NIH is a part, has the ability to reallocate funds within its budget to spare the NIH from the full effect of HHS budget reductions. Accordingly, although there is no clarity on sequestration and the NIH budget for 2013 remains uncertain, we continue to believe that a dramatic reduction in NIH funding is unlikely. In that regard, the Obama administration has already proposed a flat NIH budget for 2013, while complying with the Budget Control Act with reductions in other areas. Also, in June 2012 the Senate Committee on Appropriations approved a $100 million increase to the NIH budget for 2013 from fiscal 2012 levels. We further believe that allocations within the NIH budget will continue to favor genetic analysis tools generally and, in particular, next-generation sequencing.

Next-Generation Sequencing

Next-generation sequencing has become a core technology for modern life science research. Over the next several years, expansion of the sequencing market, including an increase in the number of samples available, and enhancements in our product portfolio will continue to drive demand for our next-generation sequencing technologies. Full commercial shipments of the HiSeq 2500 announced in Q1 2012 are expected to commence in the second half of 2012.

We experienced a sequential increase in sequencing consumable sales in Q2 2012, driven by an increase in consumable revenue per HiSeq system and growth of the installed base of our sequencing instruments. We believe that our sequencing consumable revenue will grow in future periods with the continued expansion of our installed base.

MicroArrays

As a complement to next-generation sequencing, we believe microarrays offer a less expensive, faster, and highly accurate technology for use when genetic content is already known. The information content of microarrays is fixed and reproducible. As such, microarrays provide repeatable, standardized assays for certain subsets of nucleotide bases within the overall genome. We believe that focused studies will drive future microarray sales; however, as the cost of sequencing continues to decrease, we believe that researchers will migrate certain whole genome array studies to sequencing at some point in the future.

Financial Overview

Financial highlights for the first half of 2012 include the following:

•         Net revenue decreased by 2.9% during the first half of 2012 compared to
          the same period in 2011. Revenue in the first half of 2011 benefited
          significantly from a large number of HiSeq 2000 units shipped, driven
          by the considerable backlog entering the period and the demand
          generated by our Genome Analyzer trade-in program. Revenue for the
          first half of 2012 was driven by an increase in sequencing and
          microarray consumable sales resulting from an increase in consumable
          revenue per HiSeq system, the continued growth in our instrument system
          installed base and strong demand for focused content arrays.
          Furthermore, two full quarters of MiSeq system and related consumable
          shipments further contributed to revenue in the first half of 2012.



•         Gross profit as a percentage of revenue (gross margin) was 67.6% for
          the first half of 2012, an increase from 66.9% for the first half of
          2011. We saw the positive effects of a shift in sales mix from
          instrument systems to consumables, the latter having a higher gross
          margin. We believe our gross margin in future periods will depend on
          several factors, including market conditions that may impact our
          ability to set pricing, product mix changes between consumable and
          instrument sales, cost structure for manufacturing operations, and
          creation of innovative and high premium products that meet or stimulate
          customer demand.



•         Income from operations decreased 31.6% in the first half of 2012
          compared to the same period in 2011 primarily due to a 14.4% increase
          in total operating expenses, which was driven primarily by impairment
          of in-process research and development ("IPR&D") acquired in a prior
          business combination, costs incurred to address Roche's unsolicited
          tender offer, and restructuring charges related to the restructuring
          and reduction in force announced in Q4 2011. We expect to incur
          additional expenses related to the unsolicited tender offer and our
          headquarters relocation through 2012.



•         Our effective tax rate was 33.9% for the first half of 2012. The
          provision for income taxes is dependent on the mix of earnings in tax
          jurisdictions with different statutory tax rates and the other factors
          discussed in the risk factor "We are subject to risks related to
          taxation in multiple jurisdictions and the possible loss of the tax
          deduction on our outstanding convertible notes" in Item 1A of our
          Annual Report on Form 10-K for the fiscal year ended January 1, 2012.
          For the remainder of 2012 and beyond, we anticipate that our effective
          tax rate will trend lower than the U.S. federal statutory rate as the
          portion of our earnings subject to lower statutory tax rates increases
          and the U.S. research and development tax credit is passed and
          retroactively applied for 2012.



•         We ended Q2 2012 with cash, cash equivalents, and short-term
          investments totaling $1.3 billion. During the first half of 2012, we
          generated $161.8 million in cash from operations, a $2.0 million, or
          1%, increase from the first half of 2011. During the same period, we
          used $32.5 million to repurchase shares of our common stock.

Results of Operations

To enhance comparability, the following table sets forth our unaudited condensed
consolidated statements of operations for the specified reporting periods stated
as a percentage of total revenue.

                                           Q2 2012    Q2 2011    YTD 2012    YTD 2011
Revenue:
Product revenue                             92.2  %    93.9  %     93.0  %     94.1  %
Service and other revenue                    7.8        6.1         7.0         5.9
Total revenue                              100.0      100.0       100.0       100.0
Cost of revenue:
Cost of product revenue                     26.7       29.4        28.0        29.8
Cost of service and other revenue            3.4        2.3         3.3         2.2
Amortization of acquired intangible assets   1.1        1.1         1.1         1.1
Total cost of revenue                       31.2       32.8        32.4        33.1
Gross profit                                68.8       67.3        67.6        66.9
Operating expense:
Research and development                    25.4       17.7        21.7        17.7
Selling, general and administrative         24.4       24.1        24.7        23.7
Unsolicited tender offer related expense     2.4          -         2.7           -
Restructuring charges                        0.2          -         0.6           -
Headquarter relocation expense               0.7        0.9         0.7         0.9
Acquisition related expense, net             0.4        1.7         0.5         0.9
Total operating expense                     53.5       44.4        50.9        43.2
Income from operations                      15.3       23.0        16.7        23.8
Other income (expense):
Interest income                              0.5        0.7         0.7         0.6
Interest expense                            (3.4 )     (3.3 )      (3.4 )      (2.9 )
Other expense, net                             -       (3.3 )      (0.5 )      (6.5 )
Total other expense, net                    (2.9 )     (5.9 )      (3.2 )      (8.8 )
Income before income taxes                  12.4       17.1        13.6        14.9
Provision for income taxes                   4.1        6.4         4.6         5.3
Net income                                   8.3  %    10.7  %      9.0  %      9.6  %

Our fiscal year consists of 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. The three and six month periods ended July 1, 2012 and July 3, 2011 were both 13 and 26 weeks, respectively.

Revenue

(Dollars in                                                   Percentage                                               Percentage
thousands)           Q2 2012       Q2 2011       Change         Change       YTD 2012      YTD 2011       Change         Change
Product revenue    $ 258,839     $ 269,871     $ (11,032 )       (4 )%      $ 514,475     $ 536,588     $ (22,113 )       (4 )%
Service and other
revenue               21,768        17,579         4,189         24            38,902        33,377         5,525         17
Total revenue      $ 280,607     $ 287,450     $  (6,843 )       (2 )%      $ 553,377     $ 569,965     $ (16,588 )       (3 )%

Product revenue consists primarily of revenue from the sales of consumables and instruments. Our service and other revenue is primarily generated from instrument service contracts and genotyping and sequencing services.

Q2 2012 Compared to Q2 2011

Consumables revenue increased $24.7 million, or 16%, to $183.7 million in Q2 2012 compared to $159.0 million in Q2 2011. The increase was attributable to increased sales of sequencing consumables, driven by higher consumable sales per HiSeq system and the growth of our installed base of sequencing instruments.

Instrument revenue decreased $34.5 million, or 32%, to $72.2 million in Q2 2012 compared to $106.7 million in Q2 2011, driven by a decrease in HiSeq and HiScanSQ instrument shipments, partially offset by a full quarter of MiSeq system shipments. In Q2 2011, we shipped a high volume of HiSeq 2000 units, driven by the significant backlog entering the quarter and demand from the Genome Analyzer trade-in program.

Revenue in Q2 2011 reflects the impact of discounts provided to customers under our Genome Analyzer trade-in program. The estimated incremental sales incentive provided under this trade-in program was approximately $3.7 million in Q2 2011, based on the total discount provided from list price in excess of our average discount on HiSeq 2000 sales during the period. The Genome Analyzer trade-in program was completed in Q4 2011. See "Revenue Recognition" in note "1. Summary of Significant Accounting Policies" in Part I, Item 1, of this Form 10-Q for additional information on the Genome Analyzer trade-in program.

The increase in service and other revenue in Q2 2012 compared to Q2 2011 was driven by the increase in our instrument service contract revenue as a result of our growing installed base.

YTD 2012 Compared to YTD 2011

Consumables revenue increased $49.4 million, or 16%, to $356.6 million in the first half of 2012 compared to $307.2 million in the same period in 2011. The increase was primarily attributable to increased sales of sequencing consumables, driven by higher consumable sales per HiSeq system and the growth of our installed base.

Instrument revenue decreased $69.2 million, or 31%, to $151.8 million in the first half of 2012 compared to $221.0 million in the same period in 2011, driven by a decrease in HiSeq, HiScan, and HiScanSQ instrument shipments, partially offset by two full quarters of MiSeq system shipments. In the first half of 2011, we shipped a high volume of HiSeq 2000 units, driven by the significant backlog entering the period and demand from the Genome Analyzer trade-in program.

Revenue in the first two quarters of 2011 reflects the impact of discounts provided to customers under our Genome Analyzer trade-in program. The estimated incremental sales incentive provided under this trade-in program was approximately $10.8 million for this period, based on the total discount provided from list price in excess of our average discount on HiSeq 2000 sales during the period. The Genome Analyzer trade-in program was completed in Q4 2011. See "Revenue Recognition" in note "1. Summary of Significant Accounting Policies" in Part I, Item 1, of this Form 10-Q for additional information on the Genome Analyzer trade-in program.

The increase in service and other revenue in the first half of 2012 compared to the same period in 2011 was driven by the increase in our instrument service contract revenue as a result of our growing installed base.

Gross Margin

(Dollars in                                              Percentage                                                 Percentage
thousands)      Q2 2012       Q2 2011       Change         Change         YTD 2012      YTD 2011       Change         Change
Gross profit  $ 192,997     $ 193,356     $   (359 )         -  %        $ 374,008     $ 381,397     $  (7,389 )        (2 )%
Gross margin       68.8 %        67.3 %                                       67.6 %        66.9 %

Q2 2012 Compared to Q2 2011

Gross profit in Q2 2012 is largely unchanged from Q2 2011 as the decrease in revenue was offset by a corresponding decrease in cost of goods sold. Gross margin improved in Q2 2012 due in large part to the shift in sales mix from lower margin instruments to higher margin consumables. Q2 2011 instrument sales were affected by promotional discounts provided to customers on HiSeq 2000 sales, including the Genome Analyzer trade-in program. Based on the estimated amount of incremental sales incentive provided, the Genome Analyzer trade-in program negatively impacted our gross margin by approximately 0.4% in Q2 2011. The trade-in program was completed in Q4 2011.

YTD 2012 Compared to YTD 2011

Gross profit in the first half of 2012 decreased in comparison to the same period in 2011 primarily due to lower sales. Gross margin improved in the first half of 2012 due in large part to the shift in sales mix from lower margin instruments to higher margin consumables. Instrument sales from the first half of 2011 were affected by promotional discounts provided to customers on HiSeq 2000 sales, including the Genome Analyzer trade-in program. Based on the estimated amount of incremental sales incentive provided, the Genome Analyzer trade-in program negatively impacted our gross margin by approximately 0.6% in the first half of 2011. The trade-in program was completed in Q4 2011.

Operating Expense

(Dollars in                                                  Percentage                                                Percentage
thousands)           Q2 2012       Q2 2011       Change        Change        YTD 2012      YTD 2011       Change         Change
Research and
development        $  71,223     $  50,801     $ 20,422           40  %     $ 120,062     $ 101,001     $  19,061          19  %
Selling, general
and administrative    68,516        69,233         (717 )         (1 )        136,485       134,894         1,591           1
Unsolicited tender
offer related
expense                6,694             -        6,694          100           14,786             -        14,786         100
Restructuring
charge                   674             -          674          100            3,296             -         3,296         100
Headquarter
relocation expense     1,830         2,542         (712 )        (28 )          3,970         5,064        (1,094 )       (22 )
Acquisition
related expense,
net                    1,080         4,770       (3,690 )        (77 )          2,817         5,040        (2,223 )       (44 )
Total operating
expense            $ 150,017     $ 127,346     $ 22,671           18  %     $ 281,416     $ 245,999     $  35,417          14  %

Q2 2012 Compared to Q2 2011

Research and development expense increased by $20.4 million, or 40%, in Q2 2012 from Q2 2011, primarily due to a $21.4 million impairment loss recognized for IPR&D recorded as a result of a prior acquisition, offset by a decrease in personnel expenses as a result of a restructuring and reduction in workforce in Q4 2011. Personnel expenses included salaries, share-based compensation, and benefits.

Selling, general and administrative expense in Q2 2012 is largely unchanged from Q2 2011. Although our restructuring plan and reduction in workforce announced in Q4 2011 resulted in cost savings, these benefits were offset by an increase in facilities expense as the rental fees for our current headquarters are higher than the prior facilities occupied in Q2 2011.

During Q1 2012, CKH Acquisition Corporation and Roche Holding Ltd. (together, "Roche") made an unsolicited tender offer to purchase all outstanding shares of our common stock for $51.00 per share. We recorded $6.7 million of expenses incurred in relation to the offer during Q2 2012, consisting primarily of legal, advisory, and other professional fees. Refer to note "12. Unsolicited Tender Offer" in Part I, Item 1 of this Form 10-Q for further information.

In late 2011, we announced restructuring plans to reduce our global workforce and to consolidate certain facilities. As a result of the restructuring effort, we recorded additional restructuring charges of $0.7 million during Q2 2012, comprised primarily of severance pay and other employee separation costs.

In 2011, we relocated our headquarters to another facility in San Diego, California. During Q2 2012, we incurred $1.8 million in additional headquarter relocation expense, primarily consisting of double rent expense during the transition to our new facility. Headquarter relocation expense recorded in Q2 2011 consisted of accelerated depreciation.

Acquisition related expense, net, in Q2 2012 consisted of changes in fair value of contingent consideration. Acquisition related expense, net in Q2 2011 consisted of $5.4 million in milestone payments for a prior acquisition recorded as acquired IPR&D, offset by gains related to changes in fair value of contingent consideration.

YTD 2012 Compared to YTD 2011

Research and development expense increased by $19.1 million, or 19%, in the first half of 2012 from the same period in 2011, primarily due to a $21.4 million impairment loss recognized for IPR&D recorded as a result of a prior acquisition, offset by a decrease in personnel expenses as a result of a restructuring and reduction in workforce in Q4 2011. Personnel expenses

included salaries, share-based compensation, and benefits.

Selling, general and administrative expense increased slightly in the first half of 2012 from the same period in 2011. Although our restructuring plan and reduction in workforce announced in Q4 2011 resulted in cost savings, these benefits were offset by increases in share-based compensation and facilities expense as the rental fees for our current headquarters are higher than the prior facilities occupied in the first half of 2011.

During the first half of 2012, we recorded $14.8 million of expenses incurred in relation to Roche's unsolicited tender offer, consisting primarily of legal, advisory, and other professional fees.

In late 2011, we announced restructuring plans to reduce our global workforce and to consolidate certain facilities. As a result of the restructuring effort, we recorded additional restructuring charges of $3.3 million during the first half of 2012, comprised primarily of severance pay and other employee separation costs.

In 2011, we relocated our headquarters to another facility in San Diego, California. During the first half of 2012, we incurred $4.0 million in additional headquarter relocation expense, primarily consisting of double rent expense during the transition to our new facility. Headquarter relocation expense recorded in the first half of 2011 consisted of accelerated depreciation.

Acquisition related expense, net in the first half of 2012 consisted of changes in fair value of contingent consideration. Acquisition related expense, net in the first half of 2011 consisted of $5.4 million in milestone payments for a prior acquisition recorded as acquired IPR&D, offset by gains related to changes in fair value of contingent consideration.

Other Expense, Net

                                                                Percentage                                             Percentage
(Dollars in thousands)    Q2 2012       Q2 2011      Change       Change       YTD 2012      YTD 2011       Change       Change
Interest income          $  1,385     $   1,981     $  (596 )      (30 )%     $   3,911     $   3,521     $    390         11  %
Interest expense           (9,508 )      (9,418 )       (90 )        1          (18,710 )     (16,809 )     (1,901 )       11
Other expense, net            (70 )      (9,549 )     9,479        (99 )         (2,733 )     (37,078 )     34,345        (93 )
Total other expense, net $ (8,193 )   $ (16,986 )   $ 8,793        (52 )%     $ (17,532 )   $ (50,366 )   $ 32,834        (65 )%

Q2 2012 Compared to Q2 2011

Interest income and interest expense in Q2 2012 remained largely unchanged from Q2 2011. Interest income is primarily comprised of activities resulting from our investment portfolio balance. Interest expense is primarily comprised of . . .